Research advances in connective tissue disease-associated pulmonary arterial hypertension with an emphasis on the Chinese population
By
Baocheng Liu
Zihao Wang
Xin Li
Qiyao Liu
Jingyu Zhu
May 4, 2026
Clinical Scorecard: Progress in Understanding Pulmonary Arterial Hypertension Linked to Connective Tissue Diseases in the Chinese Population
At a Glance
Category Detail
Condition Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) Key Mechanisms Elevated pulmonary arterial pressure due to connective tissue diseases, leading to right heart failure and increased mortality. Target Population Adult patients with connective tissue diseases, particularly in the Han Chinese population. Care Setting Clinical settings focusing on pulmonary hypertension diagnosis and management.
Key Highlights
CTD-PAH occurs in approximately 30% of adult PAH patients. SLE-PAH and SS-PAH are more prevalent in China compared to SSc-PAH in Europe and North America. Echocardiography is a key noninvasive tool for screening pulmonary hypertension. Right heart catheterization is the gold standard for diagnosing PAH. CTD-PAH significantly impacts quality of life and mortality in affected patients. Guideline-Based Recommendations
Diagnosis
Use echocardiography to assess the probability of pulmonary hypertension. Confirm diagnosis with right heart catheterization. Management
Initiate therapy early in populations at risk for pulmonary hypertension. Monitoring & Follow-up
Regular follow-up assessments of pulmonary arterial pressure and right heart function. Risks
Increased mortality risk associated with CTD-PAH. Patient & Prescribing Data
Patients with connective tissue diseases such as SLE, SSc, RA, PM/DM, and MCTD.
Targeted studies are needed to optimize therapeutic strategies for CTD-PAH.
Clinical Best Practices
Conduct comprehensive evaluations for patients with suspected pulmonary hypertension. Utilize multi-database literature reviews to inform clinical practices. References
